Tulliez M - Search Results

1

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.

Delgado L, Giraudier S, Ortonne N, Zehou O, Cordonnier C, Hulin A, Chosidow O, Tulliez M, Valeyrie-Allanore L. Delgado L, et al. Among authors: tulliez m. J Am Acad Dermatol. 2013 Nov;69(5):839-840. doi: 10.1016/j.jaad.2013.07.025. J Am Acad Dermatol. 2013. PMID: 24124828 No abstract available.

2

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.

Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Valeyrie L, et al. Among authors: tulliez m. J Am Acad Dermatol. 2003 Feb;48(2):201-6. doi: 10.1067/mjd.2003.44. J Am Acad Dermatol. 2003. PMID: 12582389

3

Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.

Partouche N, Conejero C, Barathon Q, Moroch J, Tulliez M, Cordonnier C, Giraudier S. Partouche N, et al. Among authors: tulliez m. Hematol Oncol. 2018 Feb;36(1):336-339. doi: 10.1002/hon.2431. Epub 2017 May 29. Hematol Oncol. 2018. PMID: 28556926

4

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L. Roux C, et al. Among authors: tulliez m. Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. Blood. 2013. PMID: 24159167 Free article. No abstract available.

5

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.

Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, LeCouedic JP, Smith DF, Larbret F, Taksin AL, Moreau-Gachelin F, Casadevall N, Tulliez M, Hulin A, Debili N, Vainchenker W. Giraudier S, et al. Among authors: tulliez m. Blood. 2002 Oct 15;100(8):2932-40. doi: 10.1182/blood-2002-02-0485. Blood. 2002. PMID: 12351405 Free article.

6

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M. Rousselot P, et al. Among authors: tulliez m. Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x. Br J Haematol. 2003. PMID: 12648085 Free article. No abstract available.

7

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.

Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, Mahon FX. Legros L, et al. Among authors: tulliez m. Blood. 2012 Aug 30;120(9):1959-60. doi: 10.1182/blood-2012-02-408229. Blood. 2012. PMID: 22936742 Free PMC article. No abstract available.

8

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

Komura E, Chagraoui H, Mansat de Mas V, Blanchet B, de Sepulveda P, Larbret F, Larghero J, Tulliez M, Debili N, Vainchenker W, Giraudier S. Komura E, et al. Among authors: tulliez m. Exp Hematol. 2003 Jul;31(7):622-30. doi: 10.1016/s0301-472x(03)00085-7. Exp Hematol. 2003. PMID: 12842707 Free article.

9

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. Among authors: tulliez m. J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323036

10

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E. Rea D, et al. Among authors: tulliez m. Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. Bull Cancer. 2016. PMID: 26790711 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters